Han, Kyu-Tae; Kim, Seungju
Journal of clinical medicine
2021May ; 10 ( 11 ) :.
PMID : 34072162
ÀúÀÚ »ó¼¼Á¤º¸
Han, Kyu-Tae - Division of Cancer Control and Policy, National Cancer Control Institute, National Cancer Center, Goyang 10408, Korea.
Kim, Seungju - Department of Nursing, College of Nursing, The Catholic University of Korea, Seoul 06591, Korea.
ABSTRACT
BACKGROUND: Statins play a role in lowering serum cholesterol and are known to have pleiotropic effects in a variety of diseases, including cancer. Despite the beneficial effects of statins in dyslipidemia patients, the treatment rate for dyslipidemia in Korea remains low, and evidence supporting the continued use of statins is lacking. The purpose of this study was to evaluate the effect of continued statin use and dosage on patient mortality after diagnosis of dyslipidemia and gastrointestinal (GI) cancer.
METHODS: We used data from the National Health Insurance Sampling (NHIS) cohort to evaluate patients diagnosed with dyslipidemia from 2002 to 2015. A total of 901 GI cancer patients with dyslipidemia and 62,727 non-cancer dyslipidemia patients were included in the study. During the study period, each patient's medication possession ratio (MPR) after diagnosis was evaluated as a measure of continued statin use. Statin dosage was measured based on a defined daily dose (DDD). Finally, we used Cox-proportional hazard ratios to identify associations between the continual use of statins and mortality in patients with dyslipidemia and GI cancer.
RESULTS: In our study, mortality decreased with increasing MPR and reached significance in MPRs exceeding 50% for GI cancer patients and 75% for dyslipidemia patients compared to patients that did not use statins. Moreover, patients with high MPRs had significantly reduced 5-year mortality compared to non-users, and cause-specific mortality analyses revealed that high MPR was associated with decreased colorectal cancer death. We did not find a significant dose-response relationship between statins and mortality. CONCLUSION: Our findings suggest that continued statin use after diagnosis is associated with reduced patient mortality. Altogether, these results support the continued use of statins in dyslipidemia patients with and without GI cancer and highlight the importance of patient education by healthcare providers.
keyword
5-year mortality; daily defined dose; dyslipidemia; gastrointestinal cancer; medication possession ratio; mortality; statin
¸µÅ©